IDEAYA Biosciences Dirección
Dirección controles de criterios 3/4
El CEO de IDEAYA Biosciences es Yujiro Hata , nombrado en Jun 2015, tiene una permanencia de 9.5 años. compensación anual total es $6.00M, compuesta por 10% salario y 90% primas, incluidas acciones y opciones de la empresa. posee directamente un 0.78% de las acciones de la empresa, por valor de $18.55M. La antigüedad media del equipo directivo y de la junta directiva es de 2 años y 6.1 años, respectivamente.
Información clave
Yujiro Hata
Chief Executive Officer (CEO)
US$6.0m
Compensación total
| Porcentaje del salario del CEO | 10.0% |
| Permanencia del CEO | 9.5yrs |
| Participación del CEO | 0.8% |
| Permanencia media de la dirección | 2yrs |
| Promedio de permanencia en la Junta Directiva | 6.1yrs |
Actualizaciones recientes de la dirección
Recent updates
Ideaya Biosciences Advances Synthetic Lethality With IDE397 Success
Sep 20Ideaya Biosciences: Poised For Success In Bladder And Lung Cancer?
Jul 08Ideaya Biosciences Continues Its Pursuit Of 'Synthetic Lethality'
Jun 18Is IDEAYA Biosciences (NASDAQ:IDYA) A Risky Investment?
Feb 22
Ideaya Biosciences: A Strong Bet In Targeted Oncology
Feb 16Analysts Are Betting On IDEAYA Biosciences, Inc. (NASDAQ:IDYA) With A Big Upgrade This Week
Nov 09Here's Why We're Not Too Worried About IDEAYA Biosciences' (NASDAQ:IDYA) Cash Burn Situation
Oct 03IDEAYA Biosciences (NASDAQ:IDYA) Is In A Good Position To Deliver On Growth Plans
Jul 04We're Not Very Worried About IDEAYA Biosciences' (NASDAQ:IDYA) Cash Burn Rate
Mar 10Here's Why We're Not Too Worried About IDEAYA Biosciences' (NASDAQ:IDYA) Cash Burn Situation
Nov 04Ideaya Biosciences: Prospects Rebound With Updated Uveal Melanoma Data
Oct 06Ideaya Biosciences slides 8.5% aftermarket on $80M stock offering
Sep 14Ideaya wins first milestone in GSK deal as cancer drug reaches clinical trials
Aug 29Analysts Have Just Cut Their IDEAYA Biosciences, Inc. (NASDAQ:IDYA) Revenue Estimates By 6.2%
Aug 25IDEAYA Biosciences GAAP EPS of -$0.57 misses by $0.05, revenue of $11.34M beats by $4.75M
Aug 15IDEAYA, Amgen in clinical trial deal for small molecule cancer agent
Jul 27Ideaya: Next 6 Months Critical For Precision Oncology Biotech
Jun 16Análisis de compensación del CEO
| Fecha | Compensación total | Salario | Ingresos de la empresa |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | -US$178m |
| Jun 30 2024 | n/a | n/a | -US$154m |
| Mar 31 2024 | n/a | n/a | -US$129m |
| Dec 31 2023 | US$6m | US$598k | -US$113m |
| Sep 30 2023 | n/a | n/a | -US$103m |
| Jun 30 2023 | n/a | n/a | -US$74m |
| Mar 31 2023 | n/a | n/a | -US$68m |
| Dec 31 2022 | US$3m | US$570k | -US$59m |
| Sep 30 2022 | n/a | n/a | -US$53m |
| Jun 30 2022 | n/a | n/a | -US$66m |
| Mar 31 2022 | n/a | n/a | -US$55m |
| Dec 31 2021 | US$4m | US$544k | -US$50m |
| Sep 30 2021 | n/a | n/a | -US$37m |
| Jun 30 2021 | n/a | n/a | -US$30m |
| Mar 31 2021 | n/a | n/a | -US$31m |
| Dec 31 2020 | US$2m | US$510k | -US$34m |
| Sep 30 2020 | n/a | n/a | -US$40m |
| Jun 30 2020 | n/a | n/a | -US$46m |
| Mar 31 2020 | n/a | n/a | -US$44m |
| Dec 31 2019 | US$2m | US$457k | -US$42m |
| Sep 30 2019 | n/a | n/a | -US$40m |
| Jun 30 2019 | n/a | n/a | -US$42m |
| Mar 31 2019 | n/a | n/a | -US$38m |
| Dec 31 2018 | US$2m | US$420k | -US$34m |
Compensación vs. Mercado: La compensación total ($USD6.00M) de Yujiro está en línea con el promedio de empresas de tamaño similar en el mercado US ($USD5.42M).
Compensación vs. Ingresos: La compensación de Yujiro ha aumentado mientras la empresa no es rentable.
CEO
Yujiro Hata (50 yo)
9.5yrs
Permanencia
US$5,995,440
Compensación
Mr. Yujiro S. Hata is Director since November 2024 at Hexagon Bio, Inc. He serves as an Independent Director at Enanta Pharmaceuticals, Inc. since August 29, 2021. He is a Co-Founder of IDEAYA Biosciences,...
Equipo directivo
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| President | 9.5yrs | US$6.00m | 0.78% $ 18.5m | |
| Principal Accounting Officer | 3.9yrs | US$1.41m | 0.028% $ 671.1k | |
| Chief Scientific Officer | 3.1yrs | US$2.76m | sin datos | |
| Chief Medical Officer | 2.1yrs | US$1.81m | 0% $ 0 | |
| Chief Technology Officer | 1.9yrs | sin datos | sin datos | |
| Senior VP & General Counsel | less than a year | sin datos | sin datos | |
| Vice President & Head of Human Resources | less than a year | sin datos | sin datos | |
| Chief of Staff & Clinical Development | 2.8yrs | sin datos | sin datos | |
| Chief Business Officer | less than a year | sin datos | sin datos | |
| Chief Commercial Officer | less than a year | sin datos | sin datos |
2.0yrs
Permanencia media
57yo
Promedio de edad
Equipo directivo experimentado: El equipo directivo de IDYA se considera experimentado (2 años antigüedad media).
Miembros de la Junta
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| President | 9.5yrs | US$6.00m | 0.78% $ 18.5m | |
| Independent Director | 5yrs | US$358.02k | 0% $ 0 | |
| Independent Director | 9.2yrs | US$363.02k | 0.0050% $ 117.1k | |
| Independent Director | 3.8yrs | US$349.52k | 0% $ 0 | |
| Chair of Scientific Advisory Board | 5.8yrs | sin datos | sin datos | |
| Independent Director | 6.4yrs | US$364.52k | 0% $ 0 | |
| Independent Director | 2.7yrs | US$350.52k | 0% $ 0 | |
| Member of Scientific Advisory Board | 8.6yrs | sin datos | sin datos | |
| Member of Scientific Advisory Board | 5.8yrs | sin datos | sin datos | |
| Member of Scientific Advisory Board | 8.6yrs | sin datos | sin datos | |
| Independent Chairman of the Board | 8.9yrs | US$369.52k | 0.019% $ 447.2k | |
| Independent Director | 4.5yrs | US$349.52k | 0% $ 0 |
6.1yrs
Permanencia media
67.5yo
Promedio de edad
Junta con experiencia: La junta directiva de IDYA se considera experimentada (6.1 años de antigüedad promedio).